Search Within

Genitourinary Oncology Service

  1. "Massachusetts Medical Society"
Formats
  1. Journal Article (41)
  2. Correspondence (7)
  3. Editorial (2)
  4. Research Letter (1)
Groups
  1. Department of Medicine (51)
  2. Solid Tumor Oncology Division (51)
  3. Hematologic Malignancies, Division of (5)
  4. GSK Faculty (4)
  5. Human Oncology and Pathogenesis Program (4)
  6. Survivorship Research (4)

More Groups

People
  1. Robert Motzer (25)
  2. Howard Scher (8)
  3. Dean Bajorin (5)
  4. David Solit (4)
  5. Jonathan Rosenberg (3)
  6. Michael Morris (3)

More People

Years
  1. 2025 (2)
  2. 2024 (2)
  3. 2023 (4)
  4. 2021 (9)
  5. 2020 (1)
  6. 2019 (2)

More Years

Publications
  1. New England Journal of Medicine (50)
  2. NEJM Evidence (1)
Publishers
  1. Massachusetts Medical Society (51)

Results (51)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Nonoperative management of mismatch repair-deficient tumors
    Journal Article

    Cercek, A.; Foote, M. B.; Rousseau, B.; Smith, J. J.; Shia, J.; Sinopoli, J.; Weiss, J.; Lumish, M.; Temple, L.; Patel, M.; more...
    New England Journal of Medicine (2025)

    Fulltext@MSK | Save
  • Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma
    Journal Article

    Apolo, A. B.; Ballman, K. V.; Sonpavde, G.; Berg, S.; Kim, W. Y.; Parikh, R.; Teo, M. Y.; Sweis, R. F.; Geynisman, D. M.; Grivas, P.; more...
    New England Journal of Medicine (2025)

    Fulltext@MSK | Save
  • Adjuvant immunotherapy for kidney cancer - A new strategy with new challenges
    Editorial

    Voss, M. H.; Motzer, R. J.
    New England Journal of Medicine (2024)

    Fulltext@MSK | Save
  • Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer
    Journal Article

    Powles, T.; Valderrama, B. P.; Gupta, S.; Bedke, J.; Kikuchi, E.; Hoffman-Censits, J.; Iyer, G.; Vulsteke, C.; Park, S. H.; Shin, S. J.; more...
    New England Journal of Medicine (2024)

    Fulltext@MSK | Save
  • An AI predictive model to determine who benefits from ADT with radiation: Working smarter, not harder
    Editorial

    Slovin, Susan F.
    NEJM Evidence (2023)

    Fulltext@MSK | Save
  • Cabozantinib plus nivolumab and ipilimumab in renal-cell carcinoma - The authors reply
    Correspondence

    Choueiri, T. K.; Wang, F.; Motzer, R. J.
    New England Journal of Medicine (2023)

    Fulltext@MSK | Save
  • Cabozantinib plus nivolumab and ipilimumab in renal-cell carcinoma
    Journal Article

    Choueiri, T. K.; Powles, T.; Albiges, L.; Burotto, M.; Szczylik, C.; Zurawski, B.; Yanez Ruiz, E.; Maruzzo, M.; Suarez Zaizar, A.; Fein, L. E.; more...
    New England Journal of Medicine (2023)

    Fulltext@MSK | Save
  • Rucaparib or physician's choice in metastatic prostate cancer
    Journal Article

    Fizazi, K.; Piulats, J. M.; Reaume, M. N.; Ostler, P.; MeDermott, R.; Gingerich, J. R.; Pintus, E.; Sridhar, S. S.; Bambury, R. M.; Emmenegger, U.; more...
    New England Journal of Medicine (2023)

    Fulltext@MSK | Save
  • Lutetium-177 - PSMA-617 for prostate cancer - The authors reply
    Correspondence

    Sartor, O.; Morris, M. J.; Kraus, B. J.
    New England Journal of Medicine (2021)

    Fulltext@MSK | Save
  • Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer
    Journal Article

    Sartor, O.; de Bono, J.; Chi, K. N.; Fizazi, K.; Herrmann, K.; Rahbar, K.; Tagawa, S. T.; Nordquist, L. T.; Vaishampayan, N.; El-Haddad, G.; more...
    New England Journal of Medicine (2021)

    Fulltext@MSK | Save